Investigations on carbon isotope ratios and concentrations of urinary formestane

Drug Testing and Analysis

Volumn 4, Issue 12, 2012, Pages 942-950

  Piper, Thomas ^a,b   Fusshöller, Gregor ^b   Emery, Caroline ^a   Schänzer, Wilhelm ^b   Saugy, Martial ^a  

^a Swiss Laboratory for Doping Analysis   (Switzerland)

^b GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Carbon isotope ratio; Doping control; Excretion study; Formestane; Reference population

Indexed keywords

CARBON; ISOTOPES; LIPIDS; PHYSIOLOGY; SPECTROMETERS;

AROMATASE INHIBITORS; CARBON ISOTOPE RATIO; DOPING CONTROL; ENDOGENOUS STEROIDS; EXCRETION STUDY; EXOGENOUS SOURCE; FORMESTANE; ISOTOPE-RATIO MASS SPECTROMETRY; REFERENCE POPULATION; WORLD ANTI-DOPING AGENCY;

MASS SPECTROMETRY;

CARBON 13; FORMESTANE;

ADULT; ARTICLE; DOPING; DRUG EXCRETION; DRUG URINE LEVEL; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; ISOTOPE ANALYSIS; ISOTOPE RATIO MASS SPECTROMETRY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; URINALYSIS; VALIDATION PROCESS;

EID: 84871376771     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.386     Document Type: Article

References (42)

1. W.C. Schwarzel, W.G. Kruggel, H.J. Brodie Studies on the mechanism of estrogen biosynthesis. VIII. The developement of inhibitors of the enzyme system in human placenta. Endocrinology 1973, 92, 866.
2. A.M.H. Brodie, C. Longcope Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3, 17-dione. Endocrinology 1980, 106, 19.
3. R.C. Coombers, P. Goss, M. Dowsett, J.C. Gazet, A. Brodie 4-hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1984, 324, 1237.
4. P.E. Goss, T.J. Powles, M. Dowsett, G. Hutchinson, A.M.H. Brodie, J.C. Gazet, et al. Treatment of advanced postmenopausal breast cancer with aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report. Cancer Res. 1986, 46, 4823.
5. P.E. Goos, M. Jarman, J.R. Wilkinson, R.C. Coombes Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat. J. Steroid Biochem. 1986, 24, 619.
6. M. Dowsett, D.C. Cunningham, R.C. Stein, S. Evans, L. Dehennin, A. Hedley, et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 1989, 49, 1306.
7. M. Dowsett, P. Lloyd Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. Cancer Chemother. Pharmacol. 1990, 27, 67.
8. G.K. Poon, M. Jarman, R. McCague, J.H. Davies, C.E.M. Heeremans, R.A.M. van der Hoeven, et al. Identification of 4-hydroxyandrost-4-ene-3, 17-dione metabolites in prostatic cancer patients by liquid chromatography-mass spectrometry. J. Chromatogr. Biomed. Appl. 1992, 576, 235.
9. M. Dowsett, A. Mehta, N. King, I.E. Smith, T.J. Powles, R.C. Stein, et al. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Eur. J. Cancer 1992, 28, 415.
10. M. Dowsett, R.C. Coombes Second generation aromatase inhibitors - 4-hydroxyandrostenedione. Breast Cancer Res. Treat. 1994, 30, 81.
11. P.E. Looning, J. Geisler, D.C. Johannessen, H.P. Gschwind, F. Waldmeier, W. Schneider, et al. Pharmacokinetics and metabolism of formestane in breast cancer patients. J. Steroid Biochem. 2001, 77, 39.
12. World Anti-Doping Agency. The 2005 Prohibited List. International Standard. Available at: www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/WADA_Prohibited_List_2005_EN.pdf [6 May 2011].
13. D.H van de Kerkhof Steroid Profiling in Doping Analysis, PhD thesis. Utrecht University, Utrecht, 2001.
14. A.T. Cawley, G.J. Trout, R. Kazlauskas, A.V. George The detection of androstenedione abuse in sport: a mass spectrometry strategy to identify the 4-hydroxyandrostenedione metabolite. Rapid Commun. Mass Spectrom. 2008, 22, 4147.
15. World Anti-Doping Agency. TD2010MRPL. Available at: www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/WADA_TD2010MRPLv1.0_Minimum%20Required%20Performance%20Levels_Sept%2001%202010_EN.pdf [6 May 2011].
16. M. Becchi, R. Aguilera, Y. Farizon, M.M. Flament, H. Casabianca, P. James Gas chromatograhy/combustion/isotope ratio mass spectrometry analysis of urinary steroids to detect misuse of testosterone in sport. Rapid Commun. Mass Spectrom. 1994, 8, 304.
17. R. Aguilera, M. Becchi, H. Casabianca, C.K. Hatton, D.H. Catlin, B. Starcevic, et al. Improved method of detection of testosterone abuse by gas chromatography/ combustion/isotope ratio mass spectrometry analysis of urinary steroids. J. Mass Spectrom. 1996, 31, 169.
18. C.H.L. Shackleton, E. Roitman, A. Phillips, T. Chang Confirming testosterone administration by isotope ratio mass spectrometry analysis of urinary androstenediols. Steroids 1997, 62, 379.
19. C. Saudan, N. Baume, P. Mangin, M. Saugy Urinary analysis of 16(5α)-androsten-3α-ol by gas chromatography/combustion/isotope ratio mass spectrometry: Implications in anti-doping analysis. J. Chromatogr. B 2004, 810, 157.
20. A.T. Cawley, R. Kazlauskas, G.J. Trout, J.H. Rogerson, A.V. George Isotopic fractionation of endogenous anabolic androgenic steroids and its relationship to doping control in sports. J. Chromatogr. Sci. 2005, 43, 32.
21. 13C-values of endogenous urinary steroids. Steroids 2008, 73, 408.
22. 12C ratios of endogenous urinary steroids: method validation, reference population and application to doping control purposes. Rapid Commun. Mass Spectrom. 2008, 22, 2161.
23. R. Aguilera, C.K. Hatton, D.H. Catlin Detection of epitestosterone doping by isotope ratio mass spectrometry. Clin. Chem. 2002, 48, 629.
24. 12C ratios of urinary epitestosterone and its main metabolites 5α- and 5β-androstane-3α, 17α-diol. Drug Test. Analysis 2009, 1, 576.
25. M. Hebestreit, U. Flenker, G. Fußhöller, H. Geyer, U. Güntner, U. Mareck, et al. Determination of the origin of urinary norandrosterone traces by gas chromatography combustion isotope ratio mass spectrometry. Analyst 2006, 131, 1021.
26. 12C ratios of urinary excreted boldenone and its main metabolite 5β-androst-1-en-17β-ol-3-one. Drug Test. Analysis 2010, 2, 217.
27. H. Craig Isotopic standards for carbon and oxygen and correction factors for mass-spectrometric analysis of carbon dioxide. Geochim. Cosmochim. Acta 1957, 12, 133.
28. World Anti-Doping Agency. TD2004EAAS. Available at: www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/Technical_Documents/WADA_TD2004EAAS_Reporting_Evaluation_Testosterone_Epitestosterone_TE_Ratio_EN.pdf [6 May 2011].
29. 13C) values of urinary steroids for doping control in sport. Steroids 2009, 74, 379.
30. 12C ratios of endogenous urinary steroids excreted as sulpho conjugates. Rapid Commun. Mass Spectrom. 2010, 24, 3171.
31. P. van Renterghem, P. van Eenoo, H. Geyer, W. Schänzer, F.T. Delbeke Reference ranges of urinary concentrations and ratios of endogenous steroids, which can be used as markers for steroid misuse, in a Caucasian population of athletes. Steroids 2010, 75, 154.
32. World Anti-Doping Agency. The 2011 Prohibited List. International Standard. Available at: www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/To_be_effective/WADA_Prohibited_List_2011_EN.pdf [6 May 2011].
33. U. Mareck, H. Geyer, G. Opfermann, M. Thevis, W. Schänzer Factors influencing the steroid profile in doping control analysis. J. Mass Spectrom. 2008, 43, 877.
34. U. Flenker, M. Hebestreit, T. Piper, F. Hülsemann, W. Schänzer Improved performance and maintenance in gas chromatography/isotope ratio mass spectrometry by precolumn solvent removal. Anal. Chem. 2007, 79, 4162.
35. 13C analysis of small polyfunctional compounds. Rapid Commun. Mass Spectrom. 2001, 15, 730.
36. C.D. Keeling The concentration and isotopic abundance of atmospheric carbon dioxide in rural areas. Geochim. Cosmochim. Acta 1958, 13, 322.
37. D.E. Pataki, J.R. Ehlering, L.B. Flanagan, D. Yakir, D.R. Bowling, C.J. Still, et al. The application and interpretation of Keeling plots in terrestrial carbon cycle research. Global Biogeochem. Cy. 2003, 17, 1022.
38. S. Rauth Referenzbereiche von urinären Steroidkonzentrationen und Steroidquotienten, PhD Thesis. German Sport University Cologne, Cologne, 1994.
39. P. Laidler, D.A. Cowan, R.C. Hider, A.T. Kicman New decision limits and quality-control material for detecting human chorionic gonadotropin misuse in sports. Clin. Chem. 1994, 40, 1306.
40. A.T. Kicman, S.B. Coutts, C.J. Walker, D.A. Cowan Proposed Confirmatory procedure for detecting 5α-dihydrotestosterone doping in male athletes. Clin. Chem. 1995, 41, 1617.
41. 12C ratios of endogenous urinary steroids investigated for doping control purposes. Drug Test. Analysis 2009, 1, 65.
42. M. Kohler, M.K. Parr, G. Opfermann, M. Thevis, N. Schlörer, F.J. Marner, et al. Metabolism of 4-hydroxyandrostenedione and 4-hydroxytestosterone: Mass spectrometric identification of urinary metabolites. Steroids 2007, 72, 278.